Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer

Published:2013-03-13 Issue:6 Volume:56 Page:2429-2446
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Liedtke Andy J.¹,Adeniji Adegoke O.²,Chen Mo²,Byrns Michael C.²,Jin Yi²,Christianson David W.³,Marnett Lawrence J.¹,Penning Trevor M.²

Affiliation:

1. Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States

2. Department of Pharmacology and Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, 1315 BRB II/III, 420 Curie Boulevard, Philadelphia, Pennsylvania 19104-6061, United States

3. Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States

Funder

National Institutes of Health

U.S. Department of Energy

National Center for Research Resources

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm3017656

Reference67 articles.